Veeva Systems (Veeva) announced that four of the top 20 pharmaceutical companies are implementing Veeva Align-a platform that swiftly produces territory alignments. Veeva Align also has new target planning capabilities to streamline multichannel cycle planning, which will integrate in Veeva CRM. Sales operations can set activity goals using criteria such as customer segmentation and sales history, prioritize customer targets, generate multichannel cycle plans, and send them directly to Veeva CRM for the field to execute.
The company also announced its new application to manage virtual events for life sciences-Veeva CRM Engage Webinar. The application manages online events without compliance risk, allowing the life sciences industry to connect with HCPs. It is built on Veeva CRM Events Management to manage physical and online events, from attendee invitations to post-event follow-up. Further, it works with Veeva Vault to share approved compliant content, as well as Veeva CRM to validate and provide a full view of HCP interaction.
Veeva further announced a new digital asset management capability for brand managers to create portals that organize and showcase content within Veeva Vault PromoMats, called Veeva Vault PromoMats Brand Portal, which should be available December 2017. The brand portal allows marketing teams to share digital assets and campaign content in one place for employees, affiliates, and agencies.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.